What is the 13F Pro Quality Score for VKTX?

13F Pro ranks Viking Therapeutics, Inc. (VKTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VKTX's current score at https://13fpro.ai/research/VKTX (free sign-up required for the full ranking).

Which hedge funds own the most VKTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VKTX include BlackRock,, FMR, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VKTX as soon as new 13F filings post.

Where does 13F Pro source VKTX data?

All Viking Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Viking Therapeutics, Inc. files with the SEC under CIK 1607678. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VKTX in?

Viking Therapeutics, Inc. (VKTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VKTX research updated on 13F Pro?

VKTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Viking Therapeutics, Inc.(VKTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1607678 VKTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VKTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Viking Therapeutics, Inc. (VKTX), a Healthcare sector company. VKTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Viking Therapeutics, Inc. reports net income of $-158.3M, free cash flow of $-114.0M. Top institutional holders of VKTX by reported 13-F value include BlackRock,, FMR, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VKTX trades on the Nasdaq exchange and files with the SEC under CIK 1607678. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viking Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-158.3M

Free Cash Flow

Q1 2026

$-114.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2024

FY20 $0.00FY21 $0.00FY23 $0.00FY24 $0.00

Net Income

-28.0% YoY

$-110.0MFY 2024

FY20 $-39.5MFY21 $-55.0MFY23 $-85.9MFY24 $-110.0M

Operating Income

-49.7% YoY

$-150.9MFY 2024

FY20 $-42.7MFY21 $-55.7MFY23 $-100.8MFY24 $-150.9M

EPS (Diluted)

-11.0% YoY

$-1.01FY 2024

FY20 —FY21 $-0.71FY23 $-0.91FY24 $-1.01

Total Assets

+146.5% YoY

$908.3MFY 2024

FY20 $256.5MFY21 $210.7MFY23 $368.5MFY24 $908.3M

Op. Cash Flow

-19.6% YoY

$-87.8MFY 2024

FY20 $-21.8MFY21 $-47.6MFY23 $-73.4MFY24 $-87.8M

Metric	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	$-110.0M -28.0%	$-85.9M -56.2%	$-55.0M -39.2%	$-39.5M -79.0%	$-22.1M -7.2%	$-20.6M
Operating Income	$-150.9M -49.7%	$-100.8M -81.1%	$-55.7M -30.5%	$-42.7M -63.1%	$-26.2M -37.2%	$-19.1M
EPS (Diluted)	$-1.01 -11.0%	$-0.91 -28.2%	$-0.71	—	—	—
Total Assets	$908.3M +146.5%	$368.5M +74.9%	$210.7M -17.9%	$256.5M -15.2%	$302.3M +1266.6%	$22.1M
Operating Cash Flow	$-87.8M -19.6%	$-73.4M -54.2%	$-47.6M -118.5%	$-21.8M -16.1%	$-18.8M -27.1%	$-14.8M

AI Insight: VKTX Financial Trends

Viking Therapeutics burned through $419M in equity over eight quarters with accelerating losses and no revenue generation.

• Net losses accelerated from $22M in Q2 2024 to $158M in Q1 2026, a 618% increase.

• Operating losses expanded from $34M in Q2 2024 to $164M in Q1 2026.

• Total equity declined from $921M in Q2 2024 to $502M in Q1 2026.

• Company remains pre-revenue with zero dollars in sales across all eight quarters.

⚠ Operating cash flow deteriorated to $114M outflow in Q1 2026 from $85M in Q4 2025.

⚠ Equity base shrinking at accelerating pace with $137M decline in latest quarter alone.

AI Insight: VKTX Ratio Trends

Viking Therapeutics shows accelerating cash burn with ROE deteriorating from -9.7% in Q2 2024 to -126.2% in Q1 2026.

• ROE declined sharply from -9.7% in Q2 2024 to -126.2% in Q1 2026, indicating mounting losses.

• ROA deteriorated from -9.4% in Q2 2024 to -88.1% in Q4 2025 before becoming unavailable.

• ROIC worsened from -14.8% in Q2 2024 to -55.3% in Q3 2025 before turning unavailable.

⚠ Missing ROA and ROIC data in Q1 2026 may signal significant balance sheet changes.

⚠ Consistent quarterly deterioration in all profitability metrics suggests unsustainable burn rate trajectory.

Get alerted when VKTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Viking Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VKTX

BlackRock, Inc.
$223.9M6,880,290 sh
FMR LLC
$196.0M6,024,753 sh
VANGUARD CAPITAL MANAGEMENT LLC
$163.1M5,012,502 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$145.3M4,464,298 sh
TWO SIGMA INVESTMENTS, LP
$144.2M4,432,142 sh
STATE STREET CORP
$143.0M4,395,557 sh
RAYMOND JAMES FINANCIAL INC
$113.5M2,075,403 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$102.8M3,158,000 sh
MORGAN STANLEY
$98.1M3,013,928 sh
GEODE CAPITAL MANAGEMENT, LLC
$67.8M2,082,067 sh

Fund	Value	Shares
BlackRock, Inc.	$223.9M	6,880,290
FMR LLC	$196.0M	6,024,753
VANGUARD CAPITAL MANAGEMENT LLC	$163.1M	5,012,502
VANGUARD PORTFOLIO MANAGEMENT LLC	$145.3M	4,464,298
TWO SIGMA INVESTMENTS, LP	$144.2M	4,432,142
STATE STREET CORP	$143.0M	4,395,557
RAYMOND JAMES FINANCIAL INC	$113.5M	2,075,403
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$102.8M	3,158,000
MORGAN STANLEY	$98.1M	3,013,928
GEODE CAPITAL MANAGEMENT, LLC	$67.8M	2,082,067

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VKTX on your watchlist

Track score changes the day Viking Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VKTX a good stock to buy?

13F Pro's AI-powered analysis of Viking Therapeutics, Inc. (VKTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VKTX are available on the VKTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VKTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VKTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Viking Therapeutics, Inc.'s investment landscape.